EUVIMEDSkopri EUVIMED
Open access

Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation

Emadeldin M Kamel iD, Ahmed A Allam, Hassan A Rudayni, Sarah I Othman, Fahad M Alshabrmi, Faris F Aba Alkhayl, Al Mokhtar Lamsabhi

ChemMedChem · 2026

DOI: 10.1002/cmdc.70470 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Emadeldin M Kamel and 6 co-authors. Institution: Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt. Major MEDLINE topics: S-Phase Kinase-Associated Proteins, CDC2-CDC28 Kinases, Quinazolines, Drug Discovery. 41 references. The full text is freely available in PubMed Central. Funded by: Ministerio de Ciencia, Innovación y Universidades, Princess Nourah bint Abdulrahman University, Princess Nora University.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The S‐phase kinase‐associated protein 2 (Skp2)–cyclin‐dependent kinase subunit 1 (Cks1) protein–protein interaction (PPI) plays a central role in recognition of phosphorylated p27 and therefore represents an attractive target for anticancer drug discovery. Herein, we sought to identify new small‐molecule disruptors of the Skp2–Cks1 interface from a focused fumiquinazoline‐scaffold library by combining virtual screening, molecular simulation, and experimental validation. Docking showed that all selected compounds occupied the Skp2–Cks1 interfacial hotspot. However, longer 1000‐ns MD simulations, comparative MM/PBSA calculations, and interface‐related metrics revealed distinct structural, energetic, and dynamic binding profiles among the selected compounds. Consistent with these analyses, comparative MM/PBSA evaluation of PPI stability showed that Fumiquinazoline D produced a positive , indicating weakening of the Skp2–Cks1 interface relative to the apo complex, whereas Ardeemin, Fiscalin A, and Fumiquinazoline F generally yielded negative values consistent with interfacial stabilization. Free energy landscape analysis further supported a more weakly confined and dynamically disruptive binding mode for Fumiquinazoline‐ D. In vitro homogeneous time‐resolved fluorescence assays validated these predictions: Fumiquinazoline D inhibited the Skp2–Cks1 interaction with an IC 50 of 6.33 ± 0.44 µM, whereas Ardeemin, Fiscalin A, and Fumiquinazoline F were substantially weaker. Although ADMET profiling identified substantial absorption and toxicity liabilities requiring future optimization, these findings identify Fumiquinazoline D as an early‐stage biochemical hit for disruption of the Skp2–Cks1 interaction and as a potential scaffold for further mechanistic validation and medicinal‐chemistry investigation.

Subjects

MeSH terms (MEDLINE)

S-Phase Kinase-Associated ProteinsCDC2-CDC28 KinasesQuinazolinesDrug DiscoveryHumansProtein BindingMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity RelationshipMolecular Structure

Author keywords

HTRF assaySkp2–Cks1fumiquinazolinesmolecular dynamicsprotein–protein interaction

Substances

S-Phase Kinase-Associated ProteinsSKP2 protein, humanCDC2-CDC28 KinasesCKS1B protein, humanQuinazolines

Authors and institutions

  • Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
  • Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
  • Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Módulo 13, Universidad Autónoma de Madrid, Madrid, Spain.

ORCID profiles: Emadeldin M Kamel

Funding

  • Ministerio de Ciencia, Innovación y Universidades
  • Princess Nourah bint Abdulrahman University
  • Princess Nora University

Cite

APA

Kamel, E. M., Allam, A. A., Rudayni, H. A., Othman, S. I., Alshabrmi, F. M., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026). Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation. ChemMedChem. https://doi.org/10.1002/cmdc.70470

Vancouver

Kamel EM, Allam AA, Rudayni HA, Othman SI, Alshabrmi FM, Alkhayl FFA, et al. Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation. ChemMedChem. 2026. doi:10.1002/cmdc.70470

BibTeX
@article{Kamel2026,
  author = {Kamel, Emadeldin M and Allam, Ahmed A and Rudayni, Hassan A and Othman, Sarah I and Alshabrmi, Fahad M and Alkhayl, Faris F Aba and Lamsabhi, Al Mokhtar},
  title = {Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70470}
}
Start for free →